nifedipine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 1922 21829-25-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BAY A1040
  • nifedipine
  • nedipin
  • fedipin
A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
  • Molecular weight: 346.34
  • Formula: C17H18N2O6
  • CLOGP: 3.12
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 1
  • TPSA: 110.45
  • ALOGS: -4.29
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O
30 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.01 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.71 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.79 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1981 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Premature delivery 442.37 9.70 298 55468 25806 53267494
Exposure during pregnancy 253.50 9.70 462 55304 124398 53168902
Premature baby 230.25 9.70 180 55586 19621 53273679
Low birth weight baby 159.39 9.70 93 55673 6244 53287056
Pre-eclampsia 151.89 9.70 101 55665 8546 53284754
Foetal exposure during pregnancy 128.98 9.70 170 55596 34545 53258755
Hypertension 115.46 9.70 504 55262 224927 53068373
Blood pressure inadequately controlled 105.18 9.70 65 55701 4846 53288454
Maternal exposure during pregnancy 90.57 9.70 362 55404 155277 53138023
Premature labour 89.98 9.70 86 55680 12276 53281024
Alopecia 84.03 9.70 73 55693 234510 53058790
Pemphigus 74.97 9.70 10 55756 104021 53189279
Hypotension 73.09 9.70 485 55281 253591 53039709
Caesarean section 72.48 9.70 90 55676 17230 53276070
Renal impairment 68.35 9.70 217 55549 83101 53210199
Oedema peripheral 67.83 9.70 355 55411 170432 53122868
Blood pressure increased 65.01 9.70 305 55461 140174 53153126
Glossodynia 62.72 9.70 14 55752 100277 53193023
Foetal growth restriction 58.16 9.70 53 55713 7121 53286179
Rheumatoid arthritis 55.26 9.70 158 55608 314373 52978927
Contraindicated product administered 53.84 9.70 38 55728 135591 53157709
Drug ineffective 50.37 9.70 580 55186 816665 52476635
Blood pressure diastolic abnormal 49.31 9.70 53 55713 8692 53284608
Neovascularisation 48.42 9.70 20 55746 627 53292673
Cardiac failure congestive 47.83 9.70 208 55558 92549 53200751
Scleroderma 46.13 9.70 40 55726 5035 53288265
Pulmonary oedema 44.11 9.70 140 55626 53583 53239717
Primary hyperaldosteronism 43.91 9.70 11 55755 61 53293239
Arthropathy 43.74 9.70 50 55716 141403 53151897
Systemic lupus erythematosus 43.69 9.70 40 55726 125374 53167926
Blood pressure systolic abnormal 43.33 9.70 45 55721 7094 53286206
Proteinuria 43.26 9.70 72 55694 17996 53275304
Dyspnoea exertional 43.05 9.70 141 55625 54859 53238441
Intestinal angioedema 41.96 9.70 18 55748 621 53292679
Discomfort 41.65 9.70 24 55742 95448 53197852
Heart rate decreased 40.70 9.70 107 55659 36840 53256460
Cerebral infarction 40.37 9.70 83 55683 24361 53268939
Oligohydramnios 39.97 9.70 40 55726 6036 53287264
Acute pulmonary oedema 39.62 9.70 46 55720 8209 53285091
Therapeutic product effect decreased 39.30 9.70 44 55722 125611 53167689
Drug dispensed to wrong patient 39.17 9.70 13 55753 216 53293084
Pericarditis 38.28 9.70 10 55756 64396 53228904
Treatment failure 37.97 9.70 47 55719 128356 53164944
Blood aldosterone increased 37.67 9.70 12 55754 174 53293126
Joint swelling 37.51 9.70 123 55643 234515 53058785
Infusion related reaction 37.43 9.70 66 55700 155891 53137409
Drug abuse 37.41 9.70 11 55755 65515 53227785
Wound 37.19 9.70 25 55741 91532 53201768
Eclampsia 36.60 9.70 14 55752 357 53292943
Transfusion 36.11 9.70 57 55709 13630 53279670
Hypergammaglobulinaemia 36.08 9.70 15 55751 478 53292822
Rectal prolapse 35.65 9.70 23 55743 1848 53291452
Rash 35.62 9.70 297 55469 445894 52847406
Polyhydramnios 34.35 9.70 24 55742 2201 53291099
Neutropenia 33.33 9.70 73 55693 159112 53134188
Rheumatoid factor positive 32.09 9.70 3 55763 41195 53252105
Bladder prolapse 31.68 9.70 22 55744 1998 53291302
Hypersensitivity 31.26 9.70 114 55652 210551 53082749
Hypertensive crisis 31.04 9.70 55 55711 14451 53278849
Renal artery stenosis 30.76 9.70 21 55745 1855 53291445
Phaeochromocytoma 30.70 9.70 14 55752 560 53292740
Sinusitis 30.05 9.70 84 55682 168480 53124820
Dialysis 30.00 9.70 45 55721 10297 53283003
CD30 expression 29.24 9.70 7 55759 31 53293269
Foetal death 29.03 9.70 42 55724 9305 53283995
Psoriasis 28.90 9.70 29 55737 87060 53206240
Injection site erythema 28.89 9.70 23 55743 77226 53216074
Dyspnoea 28.86 9.70 809 54957 585423 52707877
Blood creatinine increased 28.85 9.70 166 55600 82496 53210804
Pain 28.64 9.70 438 55328 587960 52705340
Neonatal respiratory distress syndrome 28.50 9.70 24 55742 2903 53290397
Premature separation of placenta 28.50 9.70 20 55746 1847 53291453
Bradycardia 28.36 9.70 148 55618 70908 53222392
Blood pressure systolic increased 28.26 9.70 91 55675 35086 53258214
Aplastic anaemia 28.23 9.70 39 55727 8282 53285018
Respiratory tract inflammation 27.39 9.70 13 55753 570 53292730
Tubulointerstitial nephritis 27.20 9.70 56 55710 16448 53276852
Product complaint 26.91 9.70 47 55719 12210 53281090
Angina unstable 26.84 9.70 36 55730 7432 53285868
Renin decreased 25.30 9.70 8 55758 113 53293187
Pulmonary hypertension 25.18 9.70 91 55675 37179 53256121
Porphyria acute 25.12 9.70 12 55754 534 53292766
Product residue present 24.87 9.70 26 55740 4130 53289170
Electrocardiogram PR prolongation 24.81 9.70 13 55753 706 53292594
Synovitis 24.68 9.70 47 55719 107846 53185454
Wrist deformity 24.61 9.70 18 55748 1773 53291527
Oedema 24.45 9.70 147 55619 74199 53219101
Foetal exposure timing unspecified 24.40 9.70 9 55757 207 53293093
Fatigue 24.12 9.70 581 55185 729925 52563375
Cardiac failure 24.08 9.70 163 55603 85681 53207619
Foetal distress syndrome 24.00 9.70 16 55750 1359 53291941
Infrequent bowel movements 23.39 9.70 15 55751 1193 53292107
Helicobacter infection 23.34 9.70 6 55760 39063 53254237
Patent ductus arteriosus 23.29 9.70 25 55741 4093 53289207
Thermal burn 23.20 9.70 28 55738 5205 53288095
Anuria 22.65 9.70 44 55722 12396 53280904
Fluid overload 22.36 9.70 72 55694 27759 53265541
Peripartum cardiomyopathy 22.23 9.70 8 55758 171 53293129
Injection site inflammation 22.11 9.70 22 55744 3296 53290004
Finger amputation 22.04 9.70 11 55755 539 53292761
Drug ineffective for unapproved indication 21.80 9.70 59 55707 20661 53272639
Hepatic enzyme increased 21.67 9.70 64 55702 126131 53167169
BRASH syndrome 21.56 9.70 8 55758 187 53293113
Maternal condition affecting foetus 21.44 9.70 8 55758 190 53293110
Lower respiratory tract infection 21.37 9.70 39 55727 90942 53202358
Cerebrovascular accident 21.27 9.70 185 55581 104989 53188311
Blood urea increased 21.20 9.70 68 55698 26163 53267137
HELLP syndrome 21.11 9.70 13 55753 963 53292337
Pain in jaw 20.79 9.70 91 55675 40578 53252722
Aortic dissection 20.78 9.70 16 55750 1704 53291596
Injection site reaction 20.73 9.70 14 55752 51152 53242148
Diabetic nephropathy 20.65 9.70 15 55751 1462 53291838
Drug intolerance 20.61 9.70 128 55638 205365 53087935
Endometritis 20.49 9.70 13 55753 1015 53292285
Knee arthroplasty 20.36 9.70 5 55761 33564 53259736
Paradoxical drug reaction 20.25 9.70 21 55745 3304 53289996
Cognitive disorder 19.89 9.70 11 55755 44767 53248533
Renal hypoplasia 19.49 9.70 5 55761 31 53293269
Aortic valve incompetence 19.44 9.70 28 55738 6177 53287123
Blood pressure fluctuation 19.39 9.70 81 55685 35389 53257911
Bradycardia foetal 19.11 9.70 9 55757 388 53292912
Infection 19.00 9.70 104 55662 172101 53121199
Hyperkalaemia 18.95 9.70 109 55657 54147 53239153
Blood pressure diastolic decreased 18.85 9.70 49 55717 16754 53276546
Hypovolaemic shock 18.64 9.70 26 55740 5571 53287729
Urticaria 18.55 9.70 76 55690 135809 53157491
Left ventricular hypertrophy 18.50 9.70 25 55741 5198 53288102
Peripheral vascular disorder 18.32 9.70 27 55739 6081 53287219
Abdominal discomfort 18.11 9.70 146 55620 220916 53072384
Barotrauma 18.10 9.70 7 55759 184 53293116
Foetal exposure during delivery 17.76 9.70 5 55761 46 53293254
Vascular resistance systemic increased 17.59 9.70 3 55763 0 53293300
Tocolysis 17.59 9.70 3 55763 0 53293300
Fluid retention 17.53 9.70 107 55659 54294 53239006
Respiratory distress 17.53 9.70 76 55690 33751 53259549
Uraemic encephalopathy 17.46 9.70 7 55759 203 53293097
Impaired healing 17.44 9.70 25 55741 64180 53229120
Preterm premature rupture of membranes 17.34 9.70 13 55753 1330 53291970
Vitamin D decreased 17.28 9.70 32 55734 8697 53284603
Multiple sclerosis relapse 17.22 9.70 13 55753 44840 53248460
Oral herpes 17.20 9.70 55 55711 21124 53272176
Swelling 17.17 9.70 123 55643 190982 53102318
Nephrogenic systemic fibrosis 17.16 9.70 23 55743 4744 53288556
Atrioventricular block first degree 16.94 9.70 27 55739 6508 53286792
Febrile neutropenia 16.75 9.70 55 55711 104881 53188419
Palpitations 16.69 9.70 172 55594 102176 53191124
Wrong technique in product usage process 16.68 9.70 23 55743 60009 53233291
Hypertensive emergency 16.53 9.70 14 55752 1707 53291593
Injection site pruritus 16.04 9.70 12 55754 41577 53251723
Atrial septal defect 15.82 9.70 27 55739 6887 53286413
Product substitution error 15.70 9.70 4 55762 24 53293276
Product use issue 15.56 9.70 84 55682 139500 53153800
Adverse drug reaction 15.45 9.70 20 55746 53605 53239695
Hyperuricaemia 15.43 9.70 23 55743 5233 53288067
Blood pressure decreased 15.32 9.70 114 55652 61755 53231545
Laboratory test interference 15.30 9.70 9 55757 613 53292687
Myocardial infarction 15.28 9.70 165 55601 99189 53194111
Shock 15.21 9.70 56 55710 23083 53270217
Pseudolymphoma 15.18 9.70 9 55757 622 53292678
Suicidal ideation 15.06 9.70 25 55741 60486 53232814
Malignant hypertension 14.94 9.70 11 55755 1095 53292205
Renal failure 14.79 9.70 189 55577 118263 53175037
Drug titration error 14.77 9.70 9 55757 654 53292646
Scleroderma renal crisis 14.66 9.70 7 55759 311 53292989
Ileal ulcer 14.62 9.70 8 55758 474 53292826
Hepatic rupture 14.59 9.70 4 55762 33 53293267
Injection site pain 14.50 9.70 65 55701 113326 53179974
Foetal heart rate deceleration abnormality 14.29 9.70 8 55758 496 53292804
Skin induration 14.29 9.70 17 55749 3113 53290187
Pancreatitis haemorrhagic 14.03 9.70 7 55759 343 53292957
Skin hypertrophy 13.99 9.70 17 55749 3182 53290118
Chronic kidney disease 13.78 9.70 85 55681 43285 53250015
Stillbirth 13.56 9.70 25 55741 6772 53286528
Haemoglobin decreased 13.49 9.70 210 55556 137097 53156203
Hypoaesthesia teeth 13.48 9.70 4 55762 45 53293255
Dermatophytosis of nail 13.33 9.70 4 55762 47 53293253
Human chorionic gonadotropin positive 13.33 9.70 4 55762 47 53293253
Umbilical cord vascular disorder 13.28 9.70 5 55761 122 53293178
Pulmonary embolism 13.24 9.70 68 55698 114374 53178926
Haemoperitoneum 13.17 9.70 15 55751 2622 53290678
Urine output decreased 13.14 9.70 34 55732 11589 53281711
Microvillous inclusion disease 12.98 9.70 3 55763 11 53293289
Cortisol increased 12.97 9.70 7 55759 404 53292896
Antibody test positive 12.94 9.70 14 55752 2312 53290988
Neonatal hyponatraemia 12.82 9.70 4 55762 54 53293246
Renal atrophy 12.71 9.70 11 55755 1381 53291919
Hypertensive cardiomyopathy 12.69 9.70 6 55760 261 53293039
Blood corticotrophin decreased 12.62 9.70 6 55760 264 53293036
Feeling cold 12.62 9.70 49 55717 20712 53272588
Thrombocytopenia 12.59 9.70 89 55677 138638 53154662
Cervical incompetence 12.49 9.70 8 55758 635 53292665
Cardiomegaly 12.48 9.70 44 55722 17756 53275544
Hospitalisation 12.37 9.70 121 55645 70891 53222409
Joint range of motion decreased 12.26 9.70 44 55722 17912 53275388
Coronary artery disease 12.22 9.70 68 55698 33369 53259931
Joint contracture 12.21 9.70 12 55754 1772 53291528
Therapeutic product effect incomplete 12.11 9.70 52 55714 91732 53201568
Blood lactate dehydrogenase increased 12.11 9.70 50 55716 21731 53271569
Spinal cord infarction 11.93 9.70 6 55760 299 53293001
Jaundice neonatal 11.88 9.70 9 55757 935 53292365
Systemic scleroderma 11.87 9.70 9 55757 936 53292364
Pulmonary arterial hypertension 11.87 9.70 58 55708 27064 53266236
Small for dates baby 11.86 9.70 17 55749 3735 53289565
Ventricular hypertrophy 11.81 9.70 17 55749 3748 53289552
Accidental exposure to product 11.75 9.70 5 55761 23669 53269631
Metabolic acidosis 11.71 9.70 80 55686 42162 53251138
Glomerulonephritis membranoproliferative 11.62 9.70 5 55761 174 53293126
Angina pectoris 11.57 9.70 60 55706 28665 53264635
Amniotic cavity infection 11.52 9.70 10 55756 1260 53292040
Foetal hypokinesia 11.52 9.70 7 55759 506 53292794
Transient ischaemic attack 11.34 9.70 70 55696 35655 53257645
Hypoxia 11.28 9.70 98 55668 55582 53237718
Neuromuscular blockade 11.25 9.70 6 55760 338 53292962
Gestational hypertension 11.20 9.70 13 55753 2320 53290980
Intestinal pseudo-obstruction 11.17 9.70 8 55758 763 53292537
Acute myocardial infarction 11.11 9.70 66 55700 33169 53260131
Ductus arteriosus premature closure 11.10 9.70 6 55760 347 53292953
Device expulsion 10.99 9.70 9 55757 29804 53263496
Stomatitis 10.97 9.70 59 55707 98099 53195201
Brain natriuretic peptide increased 10.96 9.70 19 55747 4906 53288394
Premature rupture of membranes 10.92 9.70 19 55747 4921 53288379
Intentional overdose 10.88 9.70 35 55731 67170 53226130
Skin tightness 10.87 9.70 17 55749 4034 53289266
Hip arthroplasty 10.79 9.70 8 55758 27854 53265446
Carotid artery disease 10.70 9.70 11 55755 1714 53291586
Hypoperfusion 10.56 9.70 10 55756 1410 53291890
Hyperplasia adrenal 10.52 9.70 3 55763 29 53293271
Right atrial enlargement 10.49 9.70 4 55762 101 53293199
Depressed mood 10.43 9.70 14 55752 36950 53256350
Shunt stenosis 10.43 9.70 6 55760 392 53292908
Arrhythmia 10.40 9.70 70 55696 36709 53256591
Live birth 10.37 9.70 37 55729 15022 53278278
Respiratory failure 10.36 9.70 155 55611 100357 53192943
Therapy partial responder 10.26 9.70 21 55745 6142 53287158
Ischaemic skin ulcer 10.26 9.70 3 55763 32 53293268
Drug interaction 10.25 9.70 301 55465 219028 53074272
Fibromyalgia 10.25 9.70 19 55747 44056 53249244
Large intestine benign neoplasm 10.21 9.70 4 55762 109 53293191
Muscle spasticity 10.17 9.70 3 55763 17835 53275465
Congenital hypothyroidism 10.06 9.70 5 55761 243 53293057
Pyuria 10.02 9.70 11 55755 1847 53291453
Peripheral ischaemia 9.96 9.70 18 55748 4801 53288499
Intracardiac mass 9.79 9.70 3 55763 38 53293262
Haemodialysis complication 9.73 9.70 5 55761 261 53293039
Hepatic function abnormal 9.71 9.70 69 55697 36830 53256470
Mallory-Weiss syndrome 9.71 9.70 10 55756 1561 53291739

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Premature baby 160.30 10.31 149 37857 18369 32457151
Foetal exposure during pregnancy 120.23 10.31 191 37815 41110 32434410
Low birth weight baby 99.46 10.31 75 37931 6919 32468601
Photodermatosis 80.72 10.31 28 37978 476 32475044
Solar lentigo 76.46 10.31 26 37980 415 32475105
Dysplastic naevus 74.17 10.31 25 37981 388 32475132
Bradycardia 67.16 10.31 210 37796 71352 32404168
Gingival hypertrophy 64.57 10.31 34 37972 1665 32473855
Hypertension 62.61 10.31 312 37694 131438 32344082
Foetal growth restriction 61.47 10.31 45 37961 3967 32471553
Off label use 57.51 10.31 176 37830 306144 32169376
Drug abuse 57.21 10.31 12 37994 80231 32395289
Cerebral infarction 53.58 10.31 107 37899 27507 32448013
Polydactyly 47.55 10.31 25 37981 1220 32474300
Hyperkalaemia 45.81 10.31 182 37824 69568 32405952
Bezoar 45.44 10.31 22 37984 900 32474620
Renal impairment 45.21 10.31 220 37786 91752 32383768
Drug ineffective 41.80 10.31 270 37736 383207 32092313
Completed suicide 39.67 10.31 213 37793 92304 32383216
Blood creatinine increased 39.65 10.31 219 37787 95913 32379607
Kidney transplant rejection 37.80 10.31 46 37960 7709 32467811
Cardiac failure congestive 36.81 10.31 196 37810 84656 32390864
Blood urea increased 36.24 10.31 101 37905 32172 32443348
Oesophageal obstruction 36.01 10.31 15 37991 428 32475092
Shock 35.95 10.31 84 37922 24030 32451490
Death 31.90 10.31 290 37716 382227 32093293
Protein urine present 31.18 10.31 34 37972 5063 32470457
Phospholipidosis 30.51 10.31 8 37998 48 32475472
Neutropenia 28.54 10.31 79 37927 142096 32333424
Chronic kidney disease 27.60 10.31 106 37900 39869 32435651
Aplasia pure red cell 27.42 10.31 34 37972 5808 32469712
Actinic keratosis 27.33 10.31 28 37978 3882 32471638
Foetal exposure timing unspecified 25.98 10.31 10 37996 231 32475289
Hypotonic-hyporesponsive episode 25.74 10.31 6 38000 20 32475500
Incision site pain 24.95 10.31 20 37986 2017 32473503
Malignant hypertension 23.36 10.31 13 37993 711 32474809
Haemodilution 23.03 10.31 6 38000 35 32475485
Pulmonary hypertension 22.87 10.31 64 37942 20430 32455090
Thrombotic cerebral infarction 22.29 10.31 10 37996 343 32475177
Cardiac arrest 22.25 10.31 191 37815 96585 32378935
Blood pressure increased 21.71 10.31 163 37843 79191 32396329
Atrioventricular block complete 21.50 10.31 38 37968 8906 32466614
Hydrops foetalis 21.47 10.31 9 37997 261 32475259
Hypotension 21.38 10.31 363 37643 215747 32259773
Proteinuria 21.17 10.31 56 37950 17299 32458221
Pyelocaliectasis 20.95 10.31 15 37991 1277 32474243
Anti-erythropoietin antibody positive 20.75 10.31 13 37993 886 32474634
Lymphocyte count decreased 20.73 10.31 63 37943 21056 32454464
Cutaneous lupus erythematosus 20.56 10.31 12 37994 719 32474801
Hepatic function abnormal 19.71 10.31 104 37902 44736 32430784
Procedural hypertension 19.69 10.31 6 38000 66 32475454
Blood pressure decreased 19.47 10.31 114 37892 50966 32424554
Fatigue 19.41 10.31 291 37715 350410 32125110
Oedema 19.36 10.31 104 37902 45043 32430477
Congenital cystic lung 19.18 10.31 8 37998 229 32475291
Treatment failure 19.11 10.31 11 37995 39152 32436368
Metabolic acidosis 19.00 10.31 96 37910 40603 32434917
HIV associated nephropathy 18.59 10.31 9 37997 368 32475152
Intestinal pseudo-obstruction 18.04 10.31 14 37992 1347 32474173
Renal failure 18 10.31 238 37768 134240 32341280
Drug dependence 17.82 10.31 3 38003 23481 32452039
Blindness 17.71 10.31 44 37962 13082 32462438
Acute kidney injury 17.59 10.31 458 37548 293010 32182510
Lacunar infarction 17.35 10.31 20 37986 3166 32472354
Mixed connective tissue disease 17.11 10.31 5 38001 47 32475473
Hypertensive crisis 16.90 10.31 34 37972 8783 32466737
Patent ductus arteriosus 16.85 10.31 20 37986 3265 32472255
Supernumerary nipple 16.66 10.31 5 38001 52 32475468
Blood pressure inadequately controlled 16.38 10.31 18 37988 2704 32472816
Caesarean section 16.20 10.31 16 37990 2123 32473397
Neonatal respiratory failure 16.02 10.31 8 37998 350 32475170
Myocardial infarction 15.82 10.31 220 37786 125456 32350064
Rickets 15.79 10.31 5 38001 63 32475457
Pulmonary eosinophilia 15.58 10.31 7 37999 241 32475279
Wrong technique in product usage process 15.53 10.31 11 37995 35048 32440472
Pituitary tumour recurrent 15.44 10.31 5 38001 68 32475452
Agitation 15.43 10.31 27 37979 57209 32418311
Polyhydramnios 15.31 10.31 7 37999 251 32475269
Sclerodactylia 15.26 10.31 4 38002 24 32475496
Oesophageal haemorrhage 15.10 10.31 12 37994 1195 32474325
Meningitis staphylococcal 15.05 10.31 5 38001 74 32475446
Rheumatoid arthritis 14.97 10.31 18 37988 44526 32430994
Naevus flammeus 14.93 10.31 6 38000 156 32475364
Renal ischaemia 14.84 10.31 9 37997 579 32474941
Congenital pulmonary valve atresia 14.81 10.31 5 38001 78 32475442
Red blood cells urine positive 14.73 10.31 14 37992 1772 32473748
Cerebrovascular accident 14.71 10.31 160 37846 86160 32389360
Therapeutic product effect incomplete 14.65 10.31 16 37990 41325 32434195
Renal failure neonatal 14.64 10.31 5 38001 81 32475439
Febrile neutropenia 14.62 10.31 81 37925 119485 32356035
Chorioretinopathy 14.60 10.31 13 37993 1514 32474006
Post procedural urine leak 14.48 10.31 6 38000 169 32475351
Pulmonary oedema 14.36 10.31 98 37908 46169 32429351
Cerebral hyperperfusion syndrome 14.20 10.31 5 38001 89 32475431
Nephrogenic systemic fibrosis 13.86 10.31 21 37985 4331 32471189
Myocardial ischaemia 13.85 10.31 49 37957 17710 32457810
Cell marker increased 13.77 10.31 8 37998 475 32475045
Acute lung injury 13.71 10.31 12 37994 1366 32474154
Aortic dissection 13.67 10.31 16 37990 2574 32472946
Blood pressure systolic 13.66 10.31 3 38003 7 32475513
Nausea 13.63 10.31 279 37727 320570 32154950
Exposure during pregnancy 13.59 10.31 32 37974 9197 32466323
Hyphaema 13.49 10.31 8 37998 494 32475026
Palatal swelling 13.47 10.31 4 38002 40 32475480
Hydrocele male infected 13.47 10.31 4 38002 40 32475480
Congenital hearing disorder 13.34 10.31 5 38001 107 32475413
Squamous cell carcinoma of skin 13.32 10.31 33 37973 9793 32465727
Neonatal respiratory distress syndrome 13.20 10.31 20 37986 4127 32471393
Prinzmetal angina 13.15 10.31 10 37996 934 32474586
Azotaemia 13.14 10.31 23 37983 5351 32470169
Cardiac cirrhosis 13.12 10.31 4 38002 44 32475476
Chronic allograft nephropathy 13.11 10.31 11 37995 1182 32474338
Bradycardia foetal 13.10 10.31 7 37999 353 32475167
Diabetes mellitus 13.04 10.31 94 37912 45079 32430441
Neutrophil count increased 13.04 10.31 45 37961 16069 32459451
Transplant rejection 12.95 10.31 33 37973 9966 32465554
Renal disorder 12.90 10.31 61 37945 25122 32450398
Drug interaction 12.89 10.31 340 37666 217845 32257675
Drug level increased 12.85 10.31 52 37954 20028 32455492
Anti-neutrophil cytoplasmic antibody positive vasculitis 12.81 10.31 9 37997 744 32474776
Infantile apnoea 12.81 10.31 10 37996 971 32474549
Photosensitivity reaction 12.60 10.31 33 37973 10130 32465390
Product residue present 12.58 10.31 16 37990 2802 32472718
Hepatocellular injury 12.51 10.31 7 37999 25311 32450209
Aplastic anaemia 12.46 10.31 27 37979 7346 32468174
Maternal exposure during pregnancy 12.45 10.31 20 37986 4337 32471183
Product use in unapproved indication 12.42 10.31 56 37950 87148 32388372
Neonatal respiratory distress 12.40 10.31 8 37998 574 32474946
Neonatal cholestasis 12.38 10.31 4 38002 54 32475466
Eating disorder symptom 12.25 10.31 3 38003 13 32475507
Brain stem infarction 12.20 10.31 11 37995 1302 32474218
Pemphigoid 12.15 10.31 29 37977 8407 32467113
Putamen haemorrhage 12.07 10.31 6 38000 260 32475260
Thrombocytopenia 12.04 10.31 113 37893 148186 32327334
Renal artery stenosis 12.01 10.31 13 37993 1920 32473600
Skin hypertrophy 11.94 10.31 15 37991 2596 32472924
Ventricular extrasystoles 11.92 10.31 36 37970 11990 32463530
Congenital musculoskeletal anomaly 11.84 10.31 6 38000 271 32475249
Haemoglobin decreased 11.79 10.31 201 37805 119470 32356050
Ventricular septal defect 11.79 10.31 18 37988 3739 32471781
Mucosal inflammation 11.78 10.31 13 37993 33421 32442099
Interstitial lung disease 11.78 10.31 122 37884 64879 32410641
Cardiac murmur 11.77 10.31 26 37980 7165 32468355
Oedema peripheral 11.75 10.31 193 37813 113898 32361622
Gastric cancer 11.68 10.31 22 37984 5415 32470105
Postrenal failure 11.60 10.31 7 37999 446 32475074
Kidney infection 11.58 10.31 21 37985 5020 32470500
Clonic convulsion 11.49 10.31 8 37998 651 32474869
Vomiting 11.48 10.31 200 37806 235357 32240163
Hypertensive emergency 11.43 10.31 9 37997 884 32474636
Maternal drugs affecting foetus 11.37 10.31 19 37987 4258 32471262
Angina unstable 11.33 10.31 36 37970 12319 32463201
Renal cyst haemorrhage 11.33 10.31 5 38001 165 32475355
Vertebral artery stenosis 11.30 10.31 5 38001 166 32475354
Tubulointerstitial nephritis 11.20 10.31 49 37957 19528 32455992
Hypocalcaemia 11.20 10.31 55 37951 22999 32452521
Apnoeic attack 11.19 10.31 6 38000 305 32475215
Anaemia neonatal 10.96 10.31 6 38000 318 32475202
Peripheral arterial occlusive disease 10.92 10.31 22 37984 5687 32469833
Systemic scleroderma 10.90 10.31 6 38000 321 32475199
White blood cell count increased 10.73 10.31 84 37922 41318 32434202
Diverticulum intestinal haemorrhagic 10.67 10.31 13 37993 2181 32473339
Delayed graft function 10.64 10.31 12 37994 1855 32473665
Neuropathy peripheral 10.63 10.31 50 37956 76932 32398588
Myocardial fibrosis 10.62 10.31 8 37998 736 32474784
Angina pectoris 10.62 10.31 68 37938 31358 32444162
Bradycardia neonatal 10.53 10.31 9 37997 992 32474528

Pharmacologic Action:

SourceCodeDescription
ATC C07FB03 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS, OTHER COMBINATIONS
Beta blocking agents and calcium channel blockers
ATC C08CA05 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Dihydropyridine derivatives
ATC C08CA55 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Dihydropyridine derivatives
ATC C08GA01 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
CALCIUM CHANNEL BLOCKERS AND DIURETICS
Calcium channel blockers and diuretics
FDA CS M0006414 Dihydropyridines
FDA MoA N0000000069 Calcium Channel Antagonists
FDA EPC N0000175421 Dihydropyridine Calcium Channel Blocker
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D012102 Reproductive Control Agents
MeSH PA D015149 Tocolytic Agents
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35620 vasodilator
CHEBI has role CHEBI:38215 calcium channel blockers
CHEBI has role CHEBI:66993 anti-contraction drug
CHEBI has role CHEBI:77746 H. sapiens metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Prinzmetal angina indication 87343002
Angina pectoris indication 194828000
Premature labor off-label use 6383007
Raynaud's phenomenon off-label use 266261006
Cirrhosis of liver contraindication 19943007 DOID:5082
Myocardial infarction contraindication 22298006 DOID:5844
Stenosis of intestine contraindication 23065003
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Chronic idiopathic constipation contraindication 82934008
Left heart failure contraindication 85232009
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Gastrointestinal obstruction contraindication 126765001
Disease of liver contraindication 235856003 DOID:409
Pyloric obstruction contraindication 244815007
Peripheral edema contraindication 271809000
Continent ileostomy - stoma contraindication 311414006
Non-Q wave myocardial infarction contraindication 314207007
Acute coronary syndrome contraindication 394659003
Porphyria contraindication 418470004
Severe Aortic Valve Stenosis contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.5 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel GATING INHIBITOR IC50 7.70 IUPHAR CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel BLOCKER Kd 9.40 CHEMBL SCIENTIFIC LITERATURE
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.30 WOMBAT-PK
Cytochrome P450 3A4 Enzyme IC50 5.26 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR Ki 6.50 PDSP
5-hydroxytryptamine receptor 2C GPCR Ki 5.02 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 5.35 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.08 CHEMBL
Glutathione reductase, mitochondrial Enzyme Ki 4.76 CHEMBL
Transthyretin Secreted IC50 5.66 WOMBAT-PK
Glycine receptor subunit alpha-1 Ion channel IC50 5.48 CHEMBL
Bile salt export pump Transporter IC50 4.51 CHEMBL
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel Ki 4.67 WOMBAT-PK
Cytochrome P450 1A2 Enzyme IC50 6.52 DRUG MATRIX
Potassium voltage-gated channel subfamily A member 1 Ion channel IC50 4.02 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1S Ion channel INHIBITOR IC50 6.30 IUPHAR
Potassium voltage-gated channel subfamily A member 5 Ion channel IC50 5.21 CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4A Enzyme IC50 4.36 DRUG MATRIX
Glycine receptor subunit beta Ion channel ANTAGONIST IC50 5.90 IUPHAR
Potassium voltage-gated channel subfamily A member 2 Ion channel Kd 4.70 WOMBAT-PK
Myosin light chain kinase, smooth muscle Kinase IC50 5.69 CHEMBL
Thromboxane-A synthase Enzyme IC50 4.73 DRUG MATRIX
C-C chemokine receptor type 2 GPCR Ki 6.07 DRUG MATRIX
Voltage-dependent L-type calcium channel subunit alpha-1F Ion channel GATING INHIBITOR IC50 6 IUPHAR
Glycine receptor subunit alpha-3 Ion channel ANTAGONIST IC50 4.50 IUPHAR
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 4.43 CHEMBL
Sodium/nucleoside cotransporter 1 Transporter Ki 5.09 DRUG MATRIX
Adenosine receptor A2a GPCR Ki 4.65 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 4.82 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 5.54 CHEMBL
Acetylcholinesterase Enzyme Ki 5.40 CHEMBL
Adenosine receptor A2a GPCR Ki 4.74 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel IC50 9 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel Ki 8.46 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel Ki 8.92 CHEMBL
Cholinesterase Enzyme Ki 5.92 CHEMBL
Indoleamine 2,3-dioxygenase 2 Enzyme IC50 5.82 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel IC50 8.59 CHEMBL
Voltage-gated L-type calcium channel Ion channel Ki 8.33 CHEMBL
Indoleamine 2,3-dioxygenase 1 Enzyme IC50 4.34 CHEMBL
Potassium voltage-gated channel subfamily A member 7 Ion channel BLOCKER IC50 4.90 IUPHAR
Potassium voltage-gated channel subfamily A member 1 Ion channel BLOCKER IC50 4 IUPHAR
Potassium voltage-gated channel subfamily A member 2 Ion channel BLOCKER Kd 4.70 IUPHAR
Potassium channel subfamily K member 2 Ion channel IC50 5.09 CHEMBL
Bile salt export pump Transporter IC50 4.34 CHEMBL

External reference:

IDSource
4018390 VUID
N0000146717 NUI
D00437 KEGG_DRUG
4018390 VANDF
C0028066 UMLSCUI
CHEBI:7565 CHEBI
C5U PDB_CHEM_ID
CHEMBL193 ChEMBL_ID
DB01115 DRUGBANK_ID
D009543 MESH_DESCRIPTOR_UI
4485 PUBCHEM_CID
2514 IUPHAR_LIGAND_ID
3222 INN_ID
I9ZF7L6G2L UNII
7417 RXNORM
2302 MMSL
5175 MMSL
d00051 MMSL
000710 NDDF
017700 NDDF
387490003 SNOMEDCT_US
85272000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Procardia XL HUMAN PRESCRIPTION DRUG LABEL 1 0069-2650 TABLET, FILM COATED, EXTENDED RELEASE 30 mg ORAL NDA 20 sections
Procardia XL HUMAN PRESCRIPTION DRUG LABEL 1 0069-2660 TABLET, FILM COATED, EXTENDED RELEASE 60 mg ORAL NDA 20 sections
Procardia XL HUMAN PRESCRIPTION DRUG LABEL 1 0069-2670 TABLET, FILM COATED, EXTENDED RELEASE 90 mg ORAL NDA 20 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 0228-2497 CAPSULE, LIQUID FILLED 10 mg ORAL ANDA 19 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 0228-2530 CAPSULE, LIQUID FILLED 20 mg ORAL ANDA 19 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 0904-7080 TABLET, EXTENDED RELEASE 30 mg ORAL ANDA 19 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 0904-7081 TABLET, EXTENDED RELEASE 60 mg ORAL ANDA 19 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 0904-7082 TABLET, EXTENDED RELEASE 90 mg ORAL ANDA 19 sections
NIFEDIPINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-319 CAPSULE, LIQUID FILLED 10 mg ORAL ANDA 19 sections
NIFEDIPINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-948 TABLET, FILM COATED, EXTENDED RELEASE 60 mg ORAL ANDA 11 sections
nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 21695-807 TABLET, FILM COATED, EXTENDED RELEASE 90 mg ORAL ANDA 20 sections
nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 21695-908 TABLET, FILM COATED, EXTENDED RELEASE 30 mg ORAL ANDA 20 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 21695-909 TABLET, EXTENDED RELEASE 60 mg ORAL ANDA 14 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 23155-194 CAPSULE 10 mg ORAL ANDA 19 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 23155-195 CAPSULE 20 mg ORAL ANDA 19 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 24979-009 TABLET, EXTENDED RELEASE 90 mg ORAL ANDA 11 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 24979-009 TABLET, EXTENDED RELEASE 90 mg ORAL ANDA 11 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 24979-010 TABLET, EXTENDED RELEASE 60 mg ORAL ANDA 11 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 24979-010 TABLET, EXTENDED RELEASE 60 mg ORAL ANDA 11 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 24979-011 TABLET, EXTENDED RELEASE 30 mg ORAL ANDA 11 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 24979-011 TABLET, EXTENDED RELEASE 30 mg ORAL ANDA 11 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 33261-840 TABLET, FILM COATED, EXTENDED RELEASE 90 mg ORAL ANDA 22 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 42192-615 CAPSULE, LIQUID FILLED 10 mg ORAL ANDA 17 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 42254-095 TABLET, FILM COATED, EXTENDED RELEASE 60 mg ORAL ANDA 22 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 43353-209 TABLET, EXTENDED RELEASE 60 mg ORAL ANDA 25 sections
AfeditabCR HUMAN PRESCRIPTION DRUG LABEL 1 43353-782 TABLET, FILM COATED, EXTENDED RELEASE 60 mg ORAL ANDA 13 sections
AfeditabCR HUMAN PRESCRIPTION DRUG LABEL 1 43353-792 TABLET, FILM COATED, EXTENDED RELEASE 30 mg ORAL ANDA 13 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 43353-929 TABLET, FILM COATED, EXTENDED RELEASE 30 mg ORAL ANDA 22 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 43386-440 CAPSULE 10 mg ORAL ANDA 19 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 50090-0695 TABLET, FILM COATED, EXTENDED RELEASE 30 mg ORAL NDA authorized generic 21 sections